Gilbert Technologies B.V.

Key People

• Maurits Huigen - Chief Executive Officer & Executive Director
• Chris Licher - Chief Financial Officer
• George Hersbach - Co-Founder, Co-Owner & Chairman
• Scott Fleming - Chief Technology Officer & Chief Commercial Officer

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The leadership team comprises individuals with over a decade of experience in their respective fields.

The leadership team's extensive experience in their respective fields provides a solid foundation for the company's strategic direction and operational execution. This depth of experience is a significant asset in navigating the complexities of the medical device industry.

Clinical Need

Aspect: Very Strong
Summary: The company's focus on pulmonary medicine addresses critical health conditions with significant unmet needs.

By developing inhalation devices for conditions such as Cystic Fibrosis, Asthma, and Lung Cancer, the company is addressing areas with high morbidity and mortality rates. The demand for effective treatments in these areas underscores the strong clinical need for their products.

Competition

Aspect: Somewhat crowded
Summary: The market for inhalation devices includes several established players, though opportunities exist for innovation.

While the inhalation device market is competitive, the company's novel approach using electrohydrodynamic atomization offers potential differentiation. Success will depend on demonstrating superior efficacy and patient outcomes compared to existing solutions.

Technical Challenge

Aspect: Moderate
Summary: Developing novel inhalation devices involves manageable technical complexities.

The development of medical devices, particularly those utilizing new technologies like electrohydrodynamic atomization, presents technical challenges. However, with a skilled team and adequate resources, these challenges are considered moderate and addressable.

Patent

Aspect: Strong
Summary: The company holds a robust patent portfolio supporting its technology.

With 20 patents, including 11 granted and 6 pending, the company has established a solid intellectual property foundation. This portfolio provides protection for its innovations and can serve as a barrier to entry for competitors.

Financing

Aspect: Well-funded
Summary: The company has secured significant funding to support its development efforts.

Raising $7.56 million in a Series A round in June 2023, along with a 2.5 million grant from the European Innovation Council Accelerator in March 2024, positions the company well to advance its product development and commercialization efforts.

Regulatory

Aspect: Pivotal Trial
Summary: The company is progressing through critical regulatory stages.

As the company advances its inhalation devices, it must successfully navigate regulatory requirements, including pivotal clinical trials, to achieve market authorization. This process is complex but crucial for product approval and commercialization.

Opportunity Rollup

Odds of Success

3.85

Peak Market Share

5.6

Segment CAGR

3.4%

Market Segment

Anesthesia and Respiratory Devices

Market Sub Segment

Inhalation Devices

Key Takeaway

Gilbert Technologies is well-positioned in the respiratory device market, leveraging innovative technology and strong financial backing to address significant clinical needs, though it faces challenges in a competitive landscape.